Increased choline signal coinciding with malignant degeneration of cerebral gliomas: A serial proton magnetic resonance spectroscopy imaging study

Journal of Neurosurgery

Volumn 87, Issue 4, 1997, Pages 516-524

  Tedeschi, Gioacchino ^b   Lundbom, Nina ^a   Raman, Ramesh ^c   Bonavita, Simona ^c   Duyn, Jeff H ^c   Alger, Jeffrey R ^c   Di Chiro, Giovanni ^c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NONE

Author keywords

Cerebral glioma; Choline; Magnetic resonance spectroscopy; Malignant degeneration; Primary brain tumor; Proton magnetic resonance spectroscopy imaging; Tumor recurrence

Indexed keywords

CHOLINE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BRAIN CANCER; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EXAMINATION; DIFFERENTIAL DIAGNOSIS; FEMALE; GLIOMA; HUMAN; MALE; MALIGNANT TRANSFORMATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 0030983951     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1997.87.4.0516     Document Type: Article

References (57)

1. Alavi JB, Alavi A, Chawluk J, et al: Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62:1074-1078, 1988
2. Alger JR, Frank, JA, Bizzi A, et al: Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 177:633-641, 1990
3. Arnold DL, Shoubridge EA, Villemure JG, et al: Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading. NMR Biomed 3:184-189, 1990
4. Barker FG II, Chang SM, Valk PE, et al: 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79:115-126, 1997
5. Barker PB, Breiter SN, Soher BJ, et al: Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med 32:157-163, 1994
6. Bizzi A, Movsas B, Tedeschi G, et al: Response of non-Hodgkin lymphoma to radiation therapy: early and long-term assessment with H-1 MR spectroscopic imaging. Radiology 194: 271-276, 1995
7. Bruhn H, Frahm J, Gyngell ML, et al: Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 172:541-548, 1989
8. Cairncross JG, Laperriere NJ: Low-grade glioma. To treat or not to treat? Arch Neurol 46:1238-1239, 1987
9. Coleman RE, Hoffman JM, Hanson MW, et al: Clinical application of PET for the evaluation of brain tumors. J Nucl Med 32:616-622, 1991
10. 18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR 14:515-523, 1993
11. 18F]Fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22:360-371, 1987
12. Di Chiro G: Which PET radiopharmaceutical for brain tumors? J Nucl Med 32:1346-1348, 1991
13. 18F] fluorodeoxyglucose and positron emission tomography. Neurology 32:1323-1329, 1982
14. Di Chiro G, Oldfield E, Wright DC, et al: Cerebral necrosis after radiation and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR 150:189-197, 1988
15. 82Rb positron emission tomography. J Comput Assist Tomogr 11:563-570, 1987
16. Duyn JH, Gillen J, Sobering G, et al: Multisection proton MR spectroscopic imaging of the brain. Radiology 188:277-282, 1993
17. Francavilla TL, Miletich RS, Di Chiro G, et al: Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 24:1-5, 1989
18. 18F]fluorodeoxyglucose (PET-FDG): an indispensable tool in the proper management of brain tumors, in Hubner KF, Coolmann J, Buonocore E, et al (eds): Clinical Positron Emission Tomography. St. Louis: Mosby Year Book, 1992, pp 50-60
19. Fulham MJ, Bizzi A, Dietz MJ, et al: Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 185:675-686, 1992
20. Fulham MJ, Di Chiro G: Neurologic PET and SPECT, in Harbert T, Eckelman W, Neumann R (eds): Textbook of Nuclear Medicine. Basel: Thieme, 1996, pp 361-385
21. Gill SS, Thomas DGT, Van Bruggen N, et al: Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J Comput Assist Tomogr 14:497-504, 1990
22. 18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 29:347-355, 1991
23. Hanson MW, Glantz MJ, Hoffman JM, et al: FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 15:796-801, 1991
24. Herholz K, Heindel W, Luyten PR, et al: In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 31:319-327, 1992
25. Herholz K, Pietrzyk U, Voges J, et al: Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79:853-858, 1993
26. Hölzer T, Herholz K, Jeske J, et al: FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 17:681-687, 1993
27. Jackson EF: In vivo magnetic resonance spectroscopy in humans: a brief review. Am J Physiol Imaging 7:146-154, 1992
28. Jaeckle KA: Clinical presentation and therapy of nervous system tumors, in Bradley WG, Daroff RB, Fenichel GM, et al (eds): Neurology in Clinical Practice: Principles of Diagnosis and Management, ed 1. Boston: Butterworth-Heimann, 1991, Vol 2, pp 1008-1030
29. Kondziolka D, Lunsford LD, Martinez AJ: Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 79: 533-536, 1993
30. Kugel H, Heindel W, Ernestus RI, et al: Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 183:701-709, 1992
31. Laws ER Jr, Taylor WF, Clifton MB, et al: Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 61:665-673, 1984
32. 18F]fluorodeoxyglucose. J Neurosurg 82:445-452, 1995
33. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for Phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
34. 1H NMR spectroscopy: N-acetyl-aspartate, creatine and choline. NMR Biomed 4:47-52, 1991
35. 1H-MRS choline: correlation with in vitro chemistry/histology. Life Sci 58: 1929-1935, 1996
36. Moffett JR, Namboodiri MAA, Neale JH: Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J Histochem Cytochem 41:559-570, 1993
37. Negendank WG, Sauter R, Brown TR, et al: Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 84:449-458, 1996
38. Ott D, Hennig J, Ernst T: Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 186:745-752, 1993
39. 18F]Fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 144:885-889, 1982
40. Patronas NJ, Di Chiro G, Kufta C, et al: Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62:816-822, 1985
41. Piepmeier JM: Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. J Neurosurg 67:177-181, 1987
42. Poptani H, Gupta RK, Roy R, et al: Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR 16:1593-1603, 1995
43. Preul MC, Caramanos Z, Collins DL, et al: Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nature Med 2:323-325, 1996
44. Prichard JW: What the clinician can learn from MRS lactate measurement. NMR Biomed 4:99-102, 1991
45. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology: Assessment: positron emission tomography. Neurology 41:163-167, 1991
46. Ross B, Michaelis T: Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 10:191-247, 1994
47. Schifter T, Hoffman JM, Hanson MW, et al: Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 17:509-516, 1993
48. 1H NMR spectroscopic imaging. Magn Reson Med 13: 62-76, 1990
49. Shapiro WR, Shapiro JR: Primary brain tumors, in Asbury AK, McKhann GM, McDonald WI (eds): Diseases of the Nervous System: Clinical Neurobiology, ed 2. Philadelphia: WB Saunders. 1992. Vol 2. pp 1074-1092
50. 1H-magnetic resonance spectroscopy of pediatric posterior fossa tumors in vitro. J Neurosurg 81:443-448, 1994
51. Taveras JM, Thompson HG Jr, Pool JL: Should we treat glioblastoma multiforme? A study of survival in 425 cases. AJR 87:473-479, 1962
52. Tedeschi G, Bertolino A, Campbell G, et al: Reproducibility of proton MR spectroscopic imaging findings. AJNR 17: 1871-1879, 1996
53. Tedeschi G, Bertolino A, Righini A, et al: Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology 45:1384-1391, 1995
54. Urenjak J, Williams SR, Gadian DG, et al: Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13:981-989, 1993
55. 1H NMR spectroscopy in vivo and in vitro. J Comput Assist Tomogr 18:705-713, 1994
56. Valk PE, Budinger TF, Levin VA, et al: PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 69:830-838, 1988
57. Zimmerman RA: Imaging of adult central nervous system primary malignant gliomas. Staging and follow-up. Cancer 67: 1278-1283, 1991